Editor: Atta-ur-Rahman

Frontiers in Clinical Drug Research – Diabetes and Obesity

Volume 5

eBook: US $69 Special Offer (PDF + Printed Copy): US $117
Printed Copy: US $83
Library License: US $276
ISSN: 2467-9607 (Print)
ISSN: 2352-3220 (Online)
ISBN: 978-1-68108-754-2 (Print)
ISBN: 978-1-68108-753-5 (Online)
Year of Publication: 2020
DOI: 10.2174/97816810875351190501


Frontiers in Clinical Drug Research – Diabetes and Obesity is a book series that brings updated reviews to readers interested in advances in the development of pharmaceutical agents for the treatment of two metabolic diseases – diabetes and obesity. The scope of the series covers a range of topics including the medicinal chemistry, pharmacology, molecular biology and biochemistry of natural and synthetic drugs affecting endocrine and metabolic processes linked with diabetes and obesity. Reviews in this series also include research on specific receptor targets and pre-clinical / clinical findings on novel pharmaceutical agents. Frontiers in Clinical Drug Research – Diabetes and Obesity is a valuable resource for pharmaceutical scientists and postgraduate students seeking updated and critically important information for developing clinical trials and devising research plans in the field of diabetes and obesity research.

The fifth volume of this series features 5 reviews which are informative guides to therapy and drug administration in diabetes and metabolic syndrome, for both the medical specialist and the pharmacologist.

-Metabolic syndrome in schizophrenia

-Insulin therapy and foetoplacental endothelial dysfunction in gestational diabetes mellitus

-Insights on diabetes, oxidative stress and antioxidant therapeutic strategies

-Administration of nano drugs in the treatment of diabetes mellitus

-SGLT-2 inhibitors


The fifth volume of Frontiers in Clinical Drug Research – Diabetes and Obesity comprises five comprehensive chapters discussing novel approaches to combat diabetes and obesity.

In the first chapter, Mandrioli et al, present the three most important classical neuroleptics (chlorpromazine, haloperidol and loxapine). The most important antipsychotics are individually analyzed in relation to their propensity to cause metabolic syndrome. In chapter 2 of the book, Sobrevia et al summarise some examples of the wide variety of protocols for insulin therapy and the potential consequences of this protocol on the foetoplacental unit and the neonate from women with Gestational diabetes mellitus (GDM).

Growing evidence suggests that hyperglycemia results in increased reactive oxygen species (ROS) production, leading to oxidative stress which affects and damages various tissues and organs. Oxidative stress results from an imbalance between ROS and antioxidants. Houreld and Rajendran highlight the understanding of oxidative stress-related mechanisms underlying the development of diabetes. Their review also elaborates on antioxidant therapy strategies to diminish oxidative stress and to treat diabetic associated complications.

Diabetes mellitus (DM) is a metabolic disorder which is the most alarming disease of the modern era. It occurs as a result of lack of insulin secretion or reduced insulin secretion or peripheral insulin resistance. In chapter 4, Anreddy et al. describe the issues concerned with the oral delivery of insulin and also discuss possible routes for the administration and use of Nanoparticles (NPs) for the best delivery of insulin.

In the last chapter of the book, Sharma et al. give comprehensive details about the merits and demerits of a class of drugs called Sodium-glucose co-transporter-2 (SGLT-2) inhibitors.

I owe special thanks to all the contributors for their valuable contributions in bringing together the fifth volume of this book series. I also thank the editorial staff of Bentham Science Publishers for their help and support.

Atta-ur-Rahman, FRS
Kings College,
University of Cambridge,